Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

Will Boggs, MD  |  April 21, 2020

NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

FDA Cautions Slower Drug Review Activity Due to Staff Reallocation for COVID-19

Reuters Staff  |  April 21, 2020

(Reuters)—On April 16, the U.S. Food & Drug Administration (FDA) cautioned that with a lot of its staff allocated to the coronavirus crisis, it may not be able to sustain its current level of timely reviews and approvals of marketing applications. FDA says it was working to ensure that the drug programs continue to see…

Novartis to Test Efficacy of Old Malaria Drug Against COVID-19

John Miller  |  April 21, 2020

ZURICH (Reuters)—Swiss drugmaker Novartis AG says it will test the malaria drug hydroxychloroquine (HCQ) in a randomized trial to see if the much talked about medicine is actually effective against COVID-19, the illness caused by the novel coronavirus. The company hopes to have data on its efficacy by June, a lead researcher for the trial…

In Memoriam: Luis R. Espinoza, MD: July 3, 1943–March 29, 2020

Joan M. Von Feldt, MD, MSEd, & Graciela S. AlarcĂ³n, MD, MPH, MACR  |  April 20, 2020

Surrounded by his immediate family, Luis R. Espinoza, MD, died on March 29 after a prolonged illness.

The COVID-19 Pandemic: What You Should Know

Jason Liebowitz, MD, FACR  |  April 20, 2020

Two rheumatologists offer advice on patient management during the COVID-19 pandemic.

FDA Considers Tanezumab Application for Chronic OA Pain

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2020

The FDA is considering an application for subcutaneous tanezumab, a monoclonal antibody, as a treatment for moderate to severe osteoarthritis…

Upper Limb Exercise May Improve Quality of Life for Lupus Patients

Lara C. Pullen, PhD  |  April 20, 2020

A recent study found SLE patients may improve their daily physical function, pain and overall quality of life by adding upper limb exercises to stable treatment regimens and routine care…

Forging New Ways to Teach in Response to COVID-19: Q&A with Anisha Dua, MD, MPH

Carina Stanton  |  April 17, 2020

Unable to connect with rheumatology fellows and patients in person, Anisha Dua, MD, MPH, and a team of rheumatologists have worked quickly to find new ways to communicate and share resources. Dr. Dua directs rheumatology medical education and the fellowship training program at Northwestern Memorial Hospital (NMH), Chicago. She spoke with The Rheumatologist about how…

Finding Opportunity Through Challenge: Q&A with Vaneet K. Sandhu, MD, FACR, RhMSUS

Carina Stanton  |  April 17, 2020

The COVID-19 global pandemic is forcing telemedicine-only connections with patients and bringing existing rheumatology research to a standstill. However, these challenges are spurring opportunity and innovation, according to Vaneet K. Sandhu, MD, FACR, RhMSUS, director of rheumatology clinical operations at Riverside University Health System and associate fellowship program director in rheumatology at Loma Linda University…

How to Maintain Connections with Colleagues, Staff & Patients During a Pandemic: A Q&A with Reshma Khan, MD

Linda Childers  |  April 17, 2020

As the cases of COVID-19 continue to rise in South Florida, Reshma Khan, MD, a rheumatologist at the Palm Beach Rheumatology and Wellness Center, Jupiter, Fla., is being careful to emphasize social distancing, but not social isolation. Dr. Khan believes that, during this pandemic, it’s more important than ever for rheumatologists to share support and…

  • « Previous Page
  • 1
  • …
  • 205
  • 206
  • 207
  • 208
  • 209
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences